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ABSTRACT Rheumatoid arthritis is a chronic systemic inflamma-
tory disease characterized by synovitis, erosions, and destruction 
of affected joints. If untreated, it leads to severe disability and 
premature mortality. Tumor necrosis factor alpha (TNF-α) inhibi-
tors are biological drugs used in treatment of rheumatoid arthri-
tis. Possible side effects include skin allergic reactions, which, if 
generalized, are the reason for discontinuation of the drug. We 
report the case of a 46-year-old female patient with rheumatoid 
arthritis who presented with pruritus and erythematous papular 
exanthema after administration of the second dose of adalimum-
ab. At first, we suspected a drug hypersensitivity reaction. As the 
signs and symptoms persisted for 2 months after discontinuation 
of adalimumab and despite continuous administration of anti-
histamines and glucocorticoids, further work-up was performed, 
and scabies was diagnosed. The patient was treated with topical 
10% crotamiton. The symptoms were persistent and additional 
applications of the preparation were needed. After clinical re-
mission of scabies, treatment of active rheumatoid arthritis with 
adalimumab was restarted without any complications.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic 
autoimmune inflammatory disease characterized 
by synovitis, erosions, and destruction of affected 
joints (1). If untreated, it leads to severe disability 
and premature mortality (2). The prevalence of RA in 
developed countries is estimated at between 0.5% 
and 1% (3). Over the last decade, the optimal use of 
conventional disease-modifying antirheumatic drugs 
(DMARDs) and the availability of new biologic drugs 
significantly contributed to the success of treatment 
and prognosis (1). 
Proinflammatory cytokines, particularly tumor 
necrosis factor alpha (TNF-α), play a critical role in 
pathogenesis of RA (4). TNF-α inhibitors are biological 
drugs used in treatment of RA (5). Possible side effects 
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include skin allergic reactions, which, if generalized, 
are the reason for discontinuation of the drug (6).
We report a 46-year-old female patient with RA 
who presented with pruritus and exanthema after 
administration of the second dose of adalimumab. At 
first we suspected a drug hypersensitivity reaction, 
but further work-up revealed scabies.
CASE REPORT
The patient with a 20-year history of RA was 
started on treatment with adalimumab due to high 
disease activity (DAS28CRP 7.05), despite treatment 
with 2 DMARDs (methotrexate and sulphasalazine) at 
maximum doses, and methylprednisolone at a dose 
of 12-16 mg daily. Adalimumab was administered 
subcutaneously at a 2-weekly dose of 40 mg. Five 
days after administration of the second dose, gener-
alized itching and rash appeared. 
The patient also had 10-year history of arterial 
hypertension, 3-year history of diabetes mellitus and 
osteopenia, and bilateral nephrolithiasis with loss of 
the excretory function of the left kidney. In addition 
to RA medications, she was taking daily urapidil at a 
dose of 120 mg, felodipine 10 mg, moxonidine 0.6 
mg, ramipril 10 mg, spironolactone 25 mg, metformin 
1000 mg and cholecalciferol 800 IU, and weekly folic 
acid at a dose of 10 mg.
The patient was examined by a rheumatologist 
on the ninth day after the appearance of symptoms. 
She reported generalized itching, which was more in-
tensive at night, and a reddish rash. Skin examination 
revealed erythematous papules and numerous linear 
excoriations in the axillary regions, under the breasts, 
on the abdomen, lower back, and both legs (Figure 1, 
2). Lymph nodes were not palpable. Adalimumab was 
discontinued because of a suspected hypersensitivity 
reaction. Over the next two months, the patient was 
successively treated with different oral antihistamines 
at maximum doses, the dose of methylprednisolone 
was increased up to 32 mg/day, and parenteral anti-
histamines and methylprednisolone were also inter-
mittently administered. She was also examined by a 
dermatologist several times. Due to the persistence 
of symptoms, the patient was hospitalized at our De-
partment for further work-up.
At admission, laboratory tests revealed mild eo-
sinophilia – eosinophil count 0.60 x109/L (normal 
values up to 0.43 x109/L), normal leukocyte count, 
and slightly elevated serum concentration of C-reac-
tive protein (CRP) – 10.8 mg/L (normal values up to 
5 mg/L). Serum immunoglobulin E (IgE) levels were 
normal. Other routine laboratory tests were in the 
reference ranges. A dermatological examination was 
performed, including skin scraping of visible lesions 
and microscopy of potassium hydroxide preparation 
of the specimen. At first, microscopical examination 
revealed no Sarcoptes mites, eggs, or eggshell frag-
ments. However, due to continued clinical suspicion, 
the skin scraping was repeated. That time, Sarcoptes 
mites were identified.
The patient was treated with topical scabicide 
– 10% crotamiton cream (two applications within a 
24-hour interval). Household members were treated 
concurrently with the same preparation. Pruritus 
and exanthema initially withdrew, but reappeared 4 
weeks later. At dermatological follow-up, skin scrap-
ing was repeated, but revealed no Sarcoptes mites, 
eggs, or eggshell fragments. Further specific treat-
ment was not recommended at the time. At subse-
quent rheumatological follow-ups, the patient was 
continuously reporting pruritus, and gradual progres-
sion of the exanthema was observed. Six months af-
ter the initial treatment of scabies, skin scraping was 
repeated and Sarcoptes mites were identified again. 
The patient was re-treated with 10% crotamiton (two 
applications within 24-hour interval). Ten days later, 
because of the persistence of signs and symptoms, 
the same treatment regimen was repeated. At further 
rheumatological follow-ups, the patient reported no 
pruritus, and complete regression of exanthema was 
observed.
Adalimumab treatment was continued 4 months 
after the clinical remission of scabies. Over the next 5 
months of follow-up, no signs or symptoms of scabies 
relapsed, and no other complications of the treat-
ment were seen. Significant control of RA activity was 
achieved (DAS28CRP 2.9). 
Figure 1. Scabies - erythematous papular exanthema 
(a) in the right armpit and (b) on the left lower leg
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DISCUSSION
Scabies is an ectoparasitic infestation caused by 
the mite Sarcoptes scabiei var hominis, an arthropod 
of the order Acarina (7). Signs and symptoms are 
caused by a delayed hypersensitivity reaction to the 
mite and its excrements, and typically include gener-
alized pruritus predominantly at night, erythematous 
papules, and pathognomonic burrows. The latter is, 
however, often not visible at examination. Crusted 
(Norwegian) scabies, a special clinical form of the dis-
ease, usually develops in immunocompromised indi-
viduals and presents with hyperkeratotic plaques and 
mild or absent pruritus (8,9). 
To our knowledge, six patients with scabies mani-
festing during the treatment with biological drugs 
have been reported in the literature. Crusted scabies 
occurred in three patients being treated for juvenile 
rheumatoid arthritis with infliximab (10), severe pso-
riasis with etanercept (11), and RA with tocilizumab 
(12). Scabies with atypical skin changes and general-
ized rash was described in two patients with ankylos-
ing spondylitis treated with adalimumab and etan-
ercept, respectively (13). In a patient with RA treated 
with adalimumab, scabies presented typically with 
pathognomonic burrows. Due to the persistency of 
symptoms, the treatment was difficult and prolonged 
(14).
In our patient, scabies presented after the second 
application of adalimumab, with generalized pruri-
tus, erythematous papular exanthema, and second-
ary excoriations (Figure 1, 2). We initially suspected 
a possible hypersensitivity reaction to the recently 
introduced drug. Due to the persistence of signs and 
symptoms despite discontinuation of adalimumab 
and continuous treatment with antihistamines and 
glucocorticoids over the following two months, the 
patient was admitted to the hospital for additional 
work-up. Although the first microscopical examina-
tion of a skin scraping specimen was negative, on our 
request the test was repeated, and diagnosis of sca-
bies was eventually established.
Treatment with crotamiton failed initially, and af-
terwards additional applications of the topical agent 
were required. A clinical study showed a significant 
elevation of serum TNF-α level in children with sca-
bies compared to the control group (15), suggesting 
possible role of the cytokine in the immunological re-
sponse of the host to the Sarcoptes mite. Initial failure 
and the need for prolonged treatment of scabies in 
our patient might be attributed to immunomodula-
tory properties of the TNF-α inhibitor, or, more likely, 
to the lack of efficacy of topical crotamiton (16). 
Several months after the achievement of com-
plete clinical remission of scabies, treatment of ac-
tive RA with adalimumab was resumed without any 
complications over the next 5 months of follow-up. 
The impact of the biological drugs on RA control was 
significant.
CONCLUSION
The aim of our case report was to emphasize the 
importance of considering scabies in differential 
diagnosis of pruritic skin lesions in patients taking 
TNF-α inhibitors. Early diagnosis and treatment of the 
infestation is essential in preventing further transmis-
sion of the disease.
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